Actelion Cites FDA Safety Rules Against Tracleer Antitrust Suit
By Bryan Koenig · February 21, 2024, 6:08 PM EST
Actelion Pharmaceuticals Ltd. said federal rules controlling distribution of potentially dangerous drugs spare it from antitrust litigation over its hypertension drug Tracleer, arguing it was required to deny needed samples to would-be...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login